--- url: 'https://qubit.capital/blog/weekly-funding-roundup-series-a-us-feb-2026-week-3' title: 'US Series B Weekly Funding Roundup: (Feb 14-20, 2026)' author: name: Mayur Toshniwal url: 'https://qubit.capital/blog/author/mayur' date: '2026-02-21T04:37:00+05:30' modified: '2026-02-21T12:20:39+05:30' type: post categories: - Weekly Funding Roundup image: 'https://qubit.capital/wp-content/uploads/2026/02/weekly-funding-roundup-series-b-uk-feb-2026-week-3.webp' published: true --- # US Series B Weekly Funding Roundup: (Feb 14-20, 2026) Across these Series B rounds, investments have been directed toward expanding technological capabilities and scaling operational platforms. The deals reflect a strong focus on AI advancements in financial services, sustainable biopolymer production, and innovative femtech solutions. Each investment highlights a commitment to growth through both market expansion and technology-enabled improvements. Table of Contents - [Uptiq Secures Series B to Boost Financial AI](#uptiq-secures-series-b-to-boost-financial-ai) [Deal overview](#deal-overview) - [Funding](#funding) - [Company Background and Leadership](#company-background-and-leadership) - [Product/Tech](#product-tech) - [Data advantage](#data-advantage) - [Vision/Positioning](#vision-positioning) - [Use of proceeds](#use-of-proceeds) - [Market context](#market-context) - [Ecovia Bio Secures Series B For Capacity Expansion](#ecovia-bio-secures-series-b-for-capacity-expansion) [Deal overview](#deal-overview-1) - [Funding](#funding-1) - [Company Background and Leadership](#company-background-and-leadership-1) - [Product/Tech](#product-tech-1) - [Data advantage](#data-advantage-1) - [Vision/Positioning](#vision-positioning-1) - [Use of proceeds](#use-of-proceeds-1) - [Market context](#market-context-1) - [Origin Drives Femtech Growth With Series B](#origin-drives-femtech-growth-with-series-b) [Deal overview](#deal-overview-2) - [Funding](#funding-2) - [Company Background and Leadership](#company-background-and-leadership-2) - [Product/Tech](#product-tech-2) - [Data advantage](#data-advantage-2) - [Vision/Positioning](#vision-positioning-2) - [Use of proceeds](#use-of-proceeds-2) - [Market context](#market-context-2) - [Lessons for Founders](#lessons-for-founders) ## Uptiq Secures Series B to Boost Financial AI ![](https://qubit.capital/wp-content/uploads/2026/02/us_series_b_feb14-20_2026.webp) ### Deal overview Deal stage: Series B | Sector: Financial services | Location: Dallas [Uptiq](https://www.uptiq.ai/) is a Dallas-based company that raised $25M in a Series B round to scale its AI solutions for the financial sector. The investment will broaden the reach of its Qore platform and enhance its global AI capabilities. ### Funding The round was a Series B for $25M led by Curql with participation from multiple investors, bolstering a track record of deployments in over 140 financial institutions. ### Company Background and Leadership The company is known for its AI platform tailored for document-heavy workflows in banks and credit unions, under the leadership of CEO Snehal Fulzele. ### Product/Tech The Qore platform powers production-ready AI applications that streamline integration with core banking systems and automate operational workflows. ### Data advantage Uptiq’s platform shows measurable improvements with 41% faster underwriting and 29% lower operational costs. ### Vision/Positioning It aims to transform financial operations by expanding its Qore platform into a self-serve model that supports rapid prototyping and deployment. ### Use of proceeds Funds will be used to deepen AI capabilities globally and expand infrastructure, including an AI research hub in India. ### Market context The investment underlines a digital transformation trend in financial services, where efficiency and compliance drive technological adoption. - Funding supports scaling AI solutions in the financial sector. - Expansion of the Qore platform may drive operational improvements at banks. ## Ecovia Bio Secures Series B For Capacity Expansion ### Deal overview Deal stage: Series B | Sector: Biotechnology | Location: Michigan [Ecovia Bio](https://ecovia-bio.com/), a Michigan-based biotechnology spinout, closed a Series B round to expand its manufacturing capacity. The funding is targeted at scaling production for its sustainable biopolymer ingredients. ### Funding The round, led by Pointe Angels, was a Series B with an undisclosed amount that underlines investor confidence in the company’s expansion plans. ### Company Background and Leadership Born as a spinout from the University of Michigan, Ecovia Bio focuses on sustainable biopolymers for industries such as cosmetics, agriculture, and personal care. ### Product/Tech It leverages a biodegradable gamma polyglutamic acid technology to provide a sustainable alternative to petrochemical-derived superabsorbent polymers. ### Data advantage The proprietary production process and academic roots offer a competitive edge in a market increasingly driven by eco-friendly solutions. ### Vision/Positioning The company aims to scale production and secure long-term supply chain stability through facility expansion. ### Use of proceeds Investments will primarily support the upgrade and expansion of its Livonia facility, with a view to future site evaluations. ### Market context The deal comes at a time when demand for eco-friendly materials is rising, fueled by environmental and health concerns. - Investment boosts ecological production capabilities. - Funding may enhance competitive positioning in sustainable biopolymers. ## Origin Drives Femtech Growth With Series B ### Deal overview Deal stage: Series B | Sector: Femtech | Geography: Brentwood [Origin](https://www.theoriginway.com/), a Brentwood-based femtech company, secured an undisclosed Series B round to expand its impact in pelvic floor and women’s health. The funds will support the scaling of its innovative care model and further integration of AI tools. ### Funding The Series B round, backed by SJF Ventures among other investors, reinforces confidence in the company’s growth strategy. ### Company Background and Leadership Specializing in pelvic floor physical therapy, Origin serves as a pivotal care provider with a network spanning 19 in-person clinic locations and a nationwide virtual platform. ### Product/Tech The company offers both physical and virtual therapy, enhanced by AI-driven tools that personalize patient care through platforms such as Athena and GinaGPT. ### Data advantage Having treated over 50,000 patients and established partnerships covering 50 million lives, Origin leads its field with measurable network scale. ### Vision/Positioning The strategy centers on leveraging technology to expand patient access and improve clinical outcomes, alongside scaling educational initiatives through Origin University. ### Use of proceeds Funds will be invested to broaden care access, enhance AI capabilities, and support ongoing research and training. ### Market context This investment reflects growing demand for accessible and technology-enabled women’s health services, particularly in the postpartum space. - Funding may expand access to specialized women health services. - Leveraging AI could improve personalized patient care. ## Lessons for Founders - Series B rounds are consistently supporting technology scaling in diverse sectors. - Geographical diversity underscores regional strengths in financial services, biotechnology, and femtech. - Investments are directed toward enhancing operational efficiencies using AI and innovative product platforms. - Each deal emphasizes the strategic use of funds for expansion and technological advancement.